# oHSV2-PD-L1/CD3-BsAb Administered Via Intratumoral Injection

> **NCT05938296** · PHASE1 · SUSPENDED · sponsor: **Binhui Biopharmaceutical Co., Ltd.** · enrollment: 29 (estimated)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** BS006 Injection

## Key facts

- **NCT ID:** NCT05938296
- **Lead sponsor:** Binhui Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2023-12-19
- **Primary completion:** 2026-12-19
- **Final completion:** 2026-12-19
- **Target enrollment:** 29 (ESTIMATED)
- **Why stopped:** Strategy adjustment
- **Last updated:** 2025-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05938296

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05938296, "oHSV2-PD-L1/CD3-BsAb Administered Via Intratumoral Injection". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05938296. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*